Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00440414
Status:
COMPLETED
Last Update Posted:
2010-08-19
First Post:
2007-02-26
Brief Title:
Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer NSCLC
Sponsor:
Hellenic Oncology Research Group
Organization:
Hellenic Oncology Research Group
Study Overview
Official Title:
A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The second-line treatment in advanced NSCLC has been currently proved effective in prolonging overall survival and improving quality of life Both pemetrexed and erlotinib have been approved for second-line treatment of NSCLC Erlotinib is a valuable option for the treatment of advanced NSCLC especially for elderly patients due to convenience of administration and safety profile The role of comprehensive geriatric assessment in treatment efficacy and tolerance is an area of investigation
Detailed Description:
This trial will compare the efficacy of pemetrexed versus erlotinib in pretreated patients with advanced NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None